---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-006923"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T01:22:23.682867+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions FY2022 revenue $161.8M (+36% YoY); GAAP net loss $139.8M on $110.4M impairment

## Summary
- Full year 2022 revenue $161.8M, up 36% vs 2021; biopreservation media revenue grew 45%.
- GAAP net loss $139.8M (includes $110.4M non-cash impairment of Stirling Ultracold intangible assets); adjusted net loss $29.3M.
- Adjusted EBITDA positive at $3.6M for full year; Q4 adjusted EBITDA $1.7M.
- Reaffirms 2023 revenue guidance of $188M-$202M, 16-25% growth; cell processing platform expected $89-93M (+30-35%).
- Cash and short-term investments $64.1M at year-end; Silicon Valley Bank operational with existing credit facilities.

## SEC filing metadata
- accession: 0001437749-23-006923
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000143774923006923/0001437749-23-006923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000143774923006923/bioli20230316_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-006923
- JSON: https://secwatch.observer/filing/0001437749-23-006923.json
- Plain text: https://secwatch.observer/filing/0001437749-23-006923.txt

## Key facts
- Earnings Releases
  BIOLIFE SOLUTIONS INC reported preliminary financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: preliminary results
  source text: On March 16, 2023, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing unaudited financial results and operational highlights for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/834365/000143774923006923/0001437749-23-006923-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.